Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Drop in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDPGet Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 51,700 shares, a decrease of 18.1% from the March 31st total of 63,100 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 55,200 shares, the short-interest ratio is presently 0.9 days.

A number of brokerages have commented on INDP. Zacks Investment Research upgraded shares of Indaptus Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, April 5th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Indaptus Therapeutics in a research report on Monday, January 31st.

Several large investors have recently added to or reduced their stakes in INDP. Marshall Wace LLP purchased a new stake in shares of Indaptus Therapeutics during the third quarter valued at approximately $100,000. Citadel Advisors LLC purchased a new stake in shares of Indaptus Therapeutics during the third quarter valued at approximately $111,000. Geode Capital Management LLC purchased a new stake in shares of Indaptus Therapeutics during the third quarter valued at approximately $214,000. Millennium Management LLC purchased a new stake in shares of Indaptus Therapeutics during the fourth quarter valued at approximately $217,000. Finally, Investment House LLC boosted its stake in shares of Indaptus Therapeutics by 272.8% during the fourth quarter. Investment House LLC now owns 95,629 shares of the company’s stock valued at $545,000 after purchasing an additional 69,976 shares during the period. 22.26% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ INDP opened at $2.91 on Friday. Indaptus Therapeutics has a one year low of $2.55 and a one year high of $28.83. The firm’s 50 day simple moving average is $3.64 and its two-hundred day simple moving average is $5.04.

About Indaptus Therapeutics (Get Rating)

Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.